Victoria Socha

DocwireNews

American Transplant Congress 2021Calcineurin inhibitors (CNI) have adverse effects on cardiovascular risk among kidney <a href="https://www.docwirenews.com/nephtimes/nephtimes-conferences/nephtimes-spring-clinical-meetings-nkf/outcomes-among-kidney-transplant-recipients-with-covid-19/">transplant</a> recipients. Conversion to belatacept may reduce the cardiovascular risk in that patient population. H. Mogallapalli conducted a study to test the hypothesis that early conversion to belatacept would result in improved patient and graft survival and lower rates of readmission within 30 days in kidney transplant recipients with congestive heart failure compared with long-term use of CNI.Results of the study were reported during a virtual session at the 2021 American Transplant Congress. The presentation was titled Association of Belatacept Conversion on Patient and Allograft Survival in Kidney Transplant Recipients with Congestive Heart Failure.The study utilized the Wisconsin Allograft Recipient Database to merge data on belatacept with the Clarity Healthline dataset that contains data on kidney transplant recipients admitted with congestive heart failure between 2014 and 2019. The International Classification of Diseases, Tenth Revision code I50 was used to identify patients with congestive heart failure and code E87.70 was used to identify patients with volume overload.Study participants who switched to belatacept were categorized into early conversion (EC, defined as switched to belatacept within 1 year of transplant) and late conversion (LC, defined as switched later than 1 year after transplant). Greedy matching was used for the EC and the LC participants based on transplant date in a 1:2 allocation ratio to CNI controls (control).The total study cohort included 301 patients. Of those, 31.5% (n=97) were in the EC group, 25.1% (n=77) were in the LC group, and 43.3% (n=133) were in the control group. Median patient survival was 2 years in the control group, 2.2 years in the EC group, and 3.4 years in the LC group (P&lt;.001). There were no significant differences among the groups in the prevalence of history of myocardial infarction, congestive heart failure, and coronary artery disease at the time of transplant.Mean time to switching to belatacept was 3.36 months in the EC group and 3.5 years in the LC group. Compared with the two belatacept groups, participants in the control group had significantly higher rate of basiliximab induction (P=.001), were more likely to have received a deceased donor transplant (P=.05), and had significantly younger donor age (43.2 years; P=.04).Results of adjusted hazard models demonstrated no statistical difference in patient survival among the three groups. There was an association between belatacept and better numerical patient and graft survival (adjusted hazard ratio [aHR], 0.36; 95% confidence interval [CI], .03-3.8; P=.4 and aHR, 0.74; 95% CI, 0.1-7.2; P=.8, respectively). There was no significant difference among the groups in the rate of readmission within 30 days (18%, 11%, and 15% in controls, EC, and LC, respectively; P=.32).In summary, the researchers said, &ldquo;Patient and graft survival and rate of admission within 30 days post congestive heart failure hospital discharge were not significantly different among the three groups. However, the patient and graft survival rates do suggest clinically protective effects of converting patients to belatacept after transplant date.&rdquo;Source: Mogallapalli H. Association of belatacept conversion in patients and allograft survival in kidney transplant recipients with congestive heart failure. Abstract of a presentation at the virtual American Transplant Congress 2021 (abstract #938), June 6, 2021.

Dr. Sadie Dobrozsi, Evolent

Rob Dillard

Genomics Tailors Breast Cancer Care, Cuts Unneeded Chemo

Genetics & Breast Cancer

Andrew Moreno

Extending Anticoagulation is Reasonable in Children with VTE, Data Suggest

Katie Kosko

DESTINY-Breast06: T-DXd Beats Chemo in HER2-Low HR+ mBC

Breast Cancer News

Latest News

Protective Effects of Converting to Belatacept Following Kidney Transplant

American Transplant Congress 2021

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe